Mass cytometry and machine learning delineate tumor-defining cells in Sézary syndrome to allow discrimination from benign erythroderma (European Journal of Cancer)

Sezary syndrome is a cutaneous (skin) lymphoma which can be hard to distinguish from atopic dermatitis, a common skin condition. Our platform was able to identify rare tumor-related cells in blood from patients with early stages of Sezary syndrome enabling the rapid and sensitive diagnosis of this life-threatening condition.

Continue reading

DLBCL white paper (potential)

While cell therapies have driven a paradigm shift in cancer treatments, they are also associated with dangerous side effects. ScaiVision helps guide treatment decisions by predicting the likelihood of neurotoxicity in patients receiving CAR-T cells to treat their lymphoma.

Continue reading